Ligand id: 8375

Name: etelcalcetide

No information available.
Summary of Clinical Use
Etelcalcetide (AMG 416) was approved by the EMA in 2016, and later by the US FDA in Feb. 2017 for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Click here to link to's listing of Phase III AMG 416 trials.
Mechanism Of Action and Pharmacodynamic Effects
The calcimimetic mechanism of etelcalcetide is distinct from that of the approved drug cinacalcet which is an allosteric modulator of the CaSR.